Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
The F.D.A. also narrowed approval of Covid shots for the season that began last fall.
- Simplified Text
-
The F.D.A. narrowed approval of Covid shots for the season that began last fall
- Confidence Score
- 0.950
- Claim Maker
- The author
- Context Type
- News Article
- Context Details
-
{ "subject": "Covid shots", "time_period": "season that began last fall", "organization_action": "narrowed approval" } - Subject Tags
- UUID
- a1164c07-51fe-4758-b48c-16e9cf93e2fe
- Vector Index
- ā No vector
- Created
- February 15, 2026 at 4:02 PM (6 months ago)
- Last Updated
- February 15, 2026 at 4:02 PM (6 months ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
30
claims
š„
1 week ago
https://nytimes.com/2026/02/10/health/fda-moderna-mrna-flu-vaccine.html
The FDA rejected Moderna's mRNA flu vaccine, signaling a shift in federal health policy under Health Secretary Robert F. Kennedy Jr. The rejection is based on concerns about the clinical trial's comparison product. Moderna's stock has plummeted since its peak.
Similar Claims (5)
Other claims identified as semantically similar to this one.
-
Simplified: The FDA notified Moderna that the agency would not review its mRNA flu vaccine6 months ago
-
Simplified: Moderna's flu shot was being developed for people 50 and older6 months ago
-
Simplified: FDA approved Novo Nordisk's Wegovy to reduce risk of major cardiovascular deaths in people with heart disease6 months ago
-
Simplified: Moderna has been harder hit than other vaccine developers as federal health officials have turned against mRNA technology and some vaccines6 months ago
-
Simplified: Moderna concluded its flu shot was superior to GSKās product6 months ago